# Tempus AI recently reported a 36.1% increase in first-quarter revenue.

*semiconductor · news · 2026-05-07 · Benzinga*

## Key points

- Tempus AI raised its full-year revenue outlook after surpassing Q1 analyst revenue expectations.
- Tempus AI's diagnostics revenue grew 34.7% from a 28% increase in oncology volume.
- Tempus AI's data and applications revenue rose 40.5% to $87 million in the first quarter.
- Ark Invest’s ARKK fund reduced its AMD holding by selling 18,909 shares valued at $8 million.
- Benzinga Edge ranks AMD stock in the 96th percentile for Momentum but only 5th for Value.

**Companies:** Advanced Micro Devices Inc, Tempus AI, Twist Bioscience Corp, Intellia Therapeutics Inc

[Read the full story on Benzinga](https://www.benzinga.com/etfs/broad-u-s-equity-etfs/26/05/52354381/cathie-wood-sells-amd-again-buys-nancy-pelosi-backed-ai-stock-ark-trade)

---

Canonical: https://newsio.io/n/a60596bf-aefc-4d96-82f8-f90e91745ad4/tempus-ai-recently-reported-a-36-1-increase-in-first-quarter-revenue-despite-wid
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works